PURPOSE: MicroRNAs (miRs) were recently recognized to be important for immune cell differentiation and immune regulation. However, whether miRs were involved in @entity6542 ( @entity6542 ) remains largely unknown. This study sought to examine changes in @entity6991 and T regulatory cells in @entity1 with persistent @entity2023 ( @entity2023 ) after 3 months of @entity9285 ( @entity9285 ) and @entity13366 ( @entity13366 ). METHODS: Twenty-four HDM-sensitized @entity1 with persistent @entity2023 were enrolled and treated with @entity9285 (n=13) or @entity13366 (n=11) for 3 months. Relative @entity6991 and @entity403 mRNA expression, the @entity10151 protein level, and the ratio of post-treatment to baseline @entity688 +CD4+ T cells between the @entity9285 and @entity13366 groups were examined in the peripheral blood mononuclear cells (PBMCs) of @entity2023 @entity1 using quantitative reverse transcription polymerase chain reaction (qRT-PCR), flow cytometry, and Western blot analysis, respectively. Serum levels of @entity225 and @entity688 were determined using ELISA. RESULTS: After 3 months of @entity6542 , both the TNSS and INSS scores were significantly decreased compared to the baseline value (P<0.01). The relative expression of @entity6991 and @entity403 mRNA was significantly increased after both @entity9285 and @entity13366 (P<0.01). The ratio of post-treatment to baseline @entity688   CD4    T cells and the serum @entity688 level were significantly increased in both the @entity9285 and @entity13366 groups (P<0.01), whereas the @entity10151 protein level and serum @entity225 level were significantly decreased (P<0.01). No significant differences in these biomarkers were observed between the @entity9285 and @entity13366 groups. CONCLUSIONS: Our findings suggest that @entity6991 and its related biomarkers may be comparably modulated after both @entity9285 and @entity13366 , highlighting @entity6991 as a potential therapeutic target for the improved management of @entity2023 .

Increased Expression of @entity6991 in @entity1 With XXXX After Allergen-Specific Immunotherapy.

@entity6542 :: ('MESH:C562465', 'Disease') :: ['allergen-specific immunotherapy', 'SIT'] @entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity225 :: ('3567', 'Gene') :: ['IL-5'] @entity9285 :: ('MESH:D013352', 'Disease') :: ['subcutaneous immunotherapy', 'SCIT'] @entity2023 :: ('MESH:D006255', 'Disease') :: ['AR', 'allergic rhinitis'] @entity10151 :: ('7189', 'Gene') :: ['TRAF6'] @entity13366 :: ('MESH:D013362', 'Disease') :: ['SLIT', 'sublingual immunotherapy'] @entity403 :: ('50943', 'Gene') :: ['Foxp3'] @entity6991 :: ('406938', 'Gene') :: ['miR-146a'] @entity688 :: ('3586', 'Gene') :: ['IL-10']
@entity2023 :: (MESH:D006255,Disease) :: ['Allergic Rhinitis']
